332 related articles for article (PubMed ID: 37895831)
1. Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies.
Kumar M; Virmani T; Kumar G; Deshmukh R; Sharma A; Duarte S; Brandão P; Fonte P
Pharmaceuticals (Basel); 2023 Sep; 16(10):. PubMed ID: 37895831
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Applications of Inorganic Nanomaterials against Tuberculosis: A Comprehensive Review.
Dastidar DG; Roy A; Ghosh G; Mandal S
Curr Drug Deliv; 2024 Apr; ():. PubMed ID: 38693736
[TBL] [Abstract][Full Text] [Related]
4. High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
Dreyer V; Mandal A; Dev P; Merker M; Barilar I; Utpatel C; Nilgiriwala K; Rodrigues C; Crook DW; ; Rasigade JP; Wirth T; Mistry N; Niemann S
Genome Med; 2022 Aug; 14(1):95. PubMed ID: 35989319
[TBL] [Abstract][Full Text] [Related]
5. Nano-Drug Delivery Systems: Possible End to the Rising Threats of Tuberculosis.
Sheikh BA; Bhat BA; Alshehri B; Mir RA; Mir WR; Parry ZA; Mir MA
J Biomed Nanotechnol; 2021 Dec; 17(12):2298-2318. PubMed ID: 34974855
[TBL] [Abstract][Full Text] [Related]
6. Innovative Therapeutic Approaches Based on Nanotechnology for the Treatment and Management of Tuberculosis.
Kia P; Ruman U; Pratiwi AR; Hussein MZ
Int J Nanomedicine; 2023; 18():1159-1191. PubMed ID: 36919095
[TBL] [Abstract][Full Text] [Related]
7. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
8. Current therapeutic delivery approaches using nanocarriers for the treatment of tuberculosis disease.
Biswas B; Misra TK; Ray D; Majumder T; Bandyopadhyay TK; Bhowmick TK
Int J Pharm; 2023 Jun; 640():123018. PubMed ID: 37149113
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistant tuberculosis - Diagnostic challenges and its conquering by nanotechnology approach - An overview.
Muthukrishnan L
Chem Biol Interact; 2021 Mar; 337():109397. PubMed ID: 33508305
[TBL] [Abstract][Full Text] [Related]
10. Nanotechnology and tuberculosis: An old disease with new treatment strategies.
Macêdo DCDS; Cavalcanti IDL; Medeiros SMFRDS; Souza JB; Lira Nogueira MCB; Cavalcanti IMF
Tuberculosis (Edinb); 2022 Jul; 135():102208. PubMed ID: 35567896
[TBL] [Abstract][Full Text] [Related]
11. Selective drug deposition in lungs through pulmonary drug delivery system for effective management of drug-resistant TB.
Sankhe K; Khan T; Bhavsar C; Momin M; Omri A
Expert Opin Drug Deliv; 2019 May; 16(5):525-538. PubMed ID: 31007100
[TBL] [Abstract][Full Text] [Related]
12. Novel and Innovative Approach of Nanotechnology with their Applications in the Management of Infectious Disease, Tuberculosis: An Overview.
Singh S; Ahuja A
Recent Pat Nanotechnol; 2024; 18(2):140-163. PubMed ID: 35616678
[TBL] [Abstract][Full Text] [Related]
13. 2 Receptor Specific Ligand Conjugated Nanocarriers: An Effective Strategy for Targeted Therapy of Tuberculosis.
Prabhu P; Fernandes T; Damani M; Chaubey P; Narayanan S; Sawarkar S
Curr Drug Deliv; 2022; 19(8):830-845. PubMed ID: 34915835
[TBL] [Abstract][Full Text] [Related]
14. Application of Lipid-Based Nanocarriers for Antitubercular Drug Delivery: A Review.
Buya AB; Witika BA; Bapolisi AM; Mwila C; Mukubwa GK; Memvanga PB; Makoni PA; Nkanga CI
Pharmaceutics; 2021 Nov; 13(12):. PubMed ID: 34959323
[TBL] [Abstract][Full Text] [Related]
15. Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
Seaworth BJ; Griffith DE
Microbiol Spectr; 2017 Mar; 5(2):. PubMed ID: 28361737
[TBL] [Abstract][Full Text] [Related]
16. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
Centers for Disease Control and Prevention (CDC)
MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
[TBL] [Abstract][Full Text] [Related]
17. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
18. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors for Multidrug-resistant Tuberculosis.
Rumende CM
Acta Med Indones; 2018 Jan; 50(1):1-2. PubMed ID: 29686169
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
